S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:CDXC

ChromaDex (CDXC) Stock Price, News & Analysis

$3.67
-0.17 (-4.43%)
(As of 03/27/2024 ET)
Today's Range
$3.55
$3.95
50-Day Range
$1.36
$3.84
52-Week Range
$1.25
$4.06
Volume
433,604 shs
Average Volume
512,408 shs
Market Capitalization
$276.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.80

ChromaDex MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
58.0% Upside
$5.80 Price Target
Short Interest
Healthy
2.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.83
Upright™ Environmental Score
News Sentiment
1.11mentions of ChromaDex in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.02) to $0.06 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.31 out of 5 stars

Medical Sector

145th out of 939 stocks

Medicinals & Botanicals Industry

1st out of 11 stocks

CDXC stock logo

About ChromaDex Stock (NASDAQ:CDXC)

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

CDXC Stock Price History

CDXC Stock News Headlines

3 Chemical Stocks Poised for Gains
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
What Wall Street expects from ChromaDex's earnings
Earnings Preview For ChromaDex
Top 3 Accelerating Chemical Stocks to Consider
ChromaDex: Growth At A Reasonable Price
ChromaDex Flat on Assistance to Military
See More Headlines
Receive CDXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/08/2023
Today
3/27/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:CDXC
Employees
106
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.80
High Stock Price Target
$6.60
Low Stock Price Target
$5.00
Potential Upside/Downside
+58.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-4,940,000.00
Pretax Margin
-5.91%

Debt

Sales & Book Value

Annual Sales
$83.57 million
Book Value
$0.38 per share

Miscellaneous

Free Float
67,349,000
Market Cap
$276.39 million
Optionable
Optionable
Beta
1.87
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Frank Louis Jaksch Jr. (Age 56)
    Co-Founder & Chairman
    Comp: $292.27k
  • Mr. Robert N. FriedMr. Robert N. Fried (Age 64)
    CEO & Director
    Comp: $735.54k
  • Ms. Brianna Gerber (Age 43)
    Chief Financial Officer
    Comp: $509.82k
  • Dr. Andrew Shao Ph.D.
    Senior Vice President of Global Regulatory & Scientific Affairs
  • Heather Van Blarcom
    Senior VP of Legal & Corporate Secretary
  • Alex Worsham
    Vice President of Global Marketing & Communications
  • Mr. David Kroes
    Senior Vice President of People Matters
  • Ms. Chu Yan
    Managing Director of Asia Pacific
  • Mr. Jason Campbell
    Senior Vice President of Business Development
  • Kendall Knysch
    Head of Media Relations & Partnerships

CDXC Stock Analysis - Frequently Asked Questions

Should I buy or sell ChromaDex stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CDXC shares.
View CDXC analyst ratings
or view top-rated stocks.

What is ChromaDex's stock price target for 2024?

1 Wall Street analysts have issued 1 year target prices for ChromaDex's stock. Their CDXC share price targets range from $5.00 to $6.60. On average, they expect the company's share price to reach $5.80 in the next year. This suggests a possible upside of 58.0% from the stock's current price.
View analysts price targets for CDXC
or view top-rated stocks among Wall Street analysts.

How have CDXC shares performed in 2024?

ChromaDex's stock was trading at $1.43 on January 1st, 2024. Since then, CDXC stock has increased by 156.6% and is now trading at $3.67.
View the best growth stocks for 2024 here
.

When is ChromaDex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CDXC earnings forecast
.

How were ChromaDex's earnings last quarter?

ChromaDex Co. (NASDAQ:CDXC) announced its earnings results on Wednesday, March, 8th. The company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.01. The business earned $21 million during the quarter, compared to analyst estimates of $21.08 million. ChromaDex had a negative net margin of 5.91% and a negative trailing twelve-month return on equity of 17.81%. During the same quarter last year, the firm earned ($0.08) earnings per share.

What is Robert Fried's approval rating as ChromaDex's CEO?

13 employees have rated ChromaDex Chief Executive Officer Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among the company's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 46.0% of employees surveyed would recommend working at ChromaDex to a friend.

What other stocks do shareholders of ChromaDex own?
Who are ChromaDex's major shareholders?

ChromaDex's stock is owned by a number of retail and institutional investors. Top institutional investors include Tieton Capital Management LLC (3.88%), Gabelli Funds LLC (0.27%), Royal Bank of Canada (0.16%), Silverberg Bernstein Capital Management LLC (0.11%), International Assets Investment Management LLC (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brianna Gerber, Frank L Jaksch Jr, Hoi Shuen Solina Holly Chau, Robert N Fried and Steven D Rubin.
View institutional ownership trends
.

How do I buy shares of ChromaDex?

Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDXC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners